ReviewCurrent directions in autoimmunity2008
Dermatomyositis.
Review in Current directions in autoimmunity, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Guideline
- Paraneoplastic Dermatomyositis in Patient with Primary Biliary Cirrhosis and Hepatocellular Carcinoma: A Case Report.The American journal of case reports · 2025Article
- Disease-linked regulatory DNA variants and homeostatic transcription factors in epidermis.Nature communications · 2025Article
- Dermatomyositis: focus on cutaneous features, etiopathogenetic mechanisms and their implications for treatment.Seminars in immunopathology · 2025Review
- Drug-induced dermatomyositis: a pharmacovigilance study of the FDA adverse event reporting system.Frontiers in pharmacology · 2025Article
- A rare case of late-onset amyloidosis cutis dyschromica.JAAD case reports · 2024Article
- Leveraging Genomic and Bioinformatic Analysis to Enhance Drug Repositioning for Dermatomyositis.Bioengineering (Basel, Switzerland) · 2023Article
- Diet, sleep, and exercise in inflammatory skin diseases.Our dermatology online · 2023Article
- Complete response to pembrolizumab in a patient with dermatomyositis and MMR deficient ovarian cancer: A case report.Gynecologic oncology reports · 2022Article
- Identification of Similarities Between Skin Lesions in Patients With Antisynthetase Syndrome and Skin Lesions in Patients With Dermatomyositis by Highly Multiplexed Imaging Mass Cytometry.Arthritis & rheumatology (Hoboken, N.J.) · 2022Article
- COVID-19 vaccine-associated dermatomyositis.JAAD case reports · 2022Article
- Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of LenabasumArthritis research & therapy · 2022Article
- Highly Multiplexed Mass Cytometry Identifies the Immunophenotype in the Skin of Dermatomyositis.The Journal of investigative dermatology · 2021Article
- Amyopathic dermatomyositis with diffuse lung disease.Journal of family medicine and primary care · 2020Article
- Dilemma in management of hemorrhagic myositis in dermatomyositis.Rheumatology international · 2020Review
- Dermatomyositis Leading to Necrotizing Vasculitis: A Perfect Response to Applied Therapy.International journal of biomedical science : IJBS · 2016Article
- Innate immune-response mechanisms in dermatomyositis: an update on pathogenesis, diagnosis and treatment.Drugs · 2014Review
- What does global gene expression profiling tell us about the pathogenesis of systemic sclerosis?Current opinion in rheumatology · 2013Review
- Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases.PloS one · 2012Article
- Tyrosine kinases in inflammatory dermatologic disease.Journal of the American Academy of Dermatology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Dermatomyositis (DM) is a chronic inflammatory disorder of the skin and muscles. Although thought to be autoimmune in origin, many questions remain as to the etiopathogenesis of this disease. DM has classically been considered a humorally mediated disease. Current evidence, however, seems to increasingly support alternative (though not mutually exclusive) mechanisms of pathogenesis, including cell-mediated and innate immune system dysfunction. Pathologic findings of DM in muscle include infarcts, perifascicular atrophy, endothelial cell swelling and necrosis, vessel wall membrane attack complex deposition, and myocyte-specific MHC I upregulation. As for the skin, histopathologic findings include hyperkeratosis, epidermal basal cell vacuolar degeneration and apoptosis, increased dermal mucin deposition, and a cell-poor interface dermatitis. Autoantibodies, particularly those that bind nuclear or cytoplasmic ribonucleoprotein antigens, are also commonly found in DM, although their importance in pathogenesis remains unclear. Defective cellular clearance, genetic predilection and environmental exposures, such as viral infection, may also play an important role in the pathogenesis of DM. The seminal work regarding the pathogenesis of DM is reviewed and an update on the recent basic and molecular advances in the field is provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.